 Bradford Siegele
Concepts (116)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Burkitt Lymphoma | 2 | 2022 | 52 | 0.970 |
Why?
| | Leukemia, Hairy Cell | 1 | 2018 | 6 | 0.640 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 256 | 0.640 |
Why?
| | Pancytopenia | 1 | 2018 | 7 | 0.630 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 64 | 0.570 |
Why?
| | Sarcoma | 1 | 2017 | 137 | 0.500 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2017 | 179 | 0.500 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2016 | 77 | 0.490 |
Why?
| | Homeodomain Proteins | 1 | 2017 | 464 | 0.440 |
Why?
| | Immunohistochemistry | 5 | 2022 | 1634 | 0.430 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2022 | 577 | 0.420 |
Why?
| | ErbB Receptors | 1 | 2016 | 555 | 0.420 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 1353 | 0.410 |
Why?
| | Leukemia, Myeloid, Acute | 3 | 2024 | 534 | 0.370 |
Why?
| | Mutation | 2 | 2024 | 3350 | 0.370 |
Why?
| | Biomarkers, Tumor | 1 | 2017 | 1045 | 0.360 |
Why?
| | Head and Neck Neoplasms | 2 | 2018 | 427 | 0.340 |
Why?
| | Eukaryotic Initiation Factor-4E | 1 | 2008 | 27 | 0.310 |
Why?
| | Diagnosis, Differential | 4 | 2018 | 1355 | 0.270 |
Why?
| | Genetic Therapy | 1 | 2008 | 258 | 0.270 |
Why?
| | Neoplasm, Residual | 2 | 2024 | 104 | 0.260 |
Why?
| | Neoplasm Metastasis | 1 | 2008 | 524 | 0.260 |
Why?
| | Azacitidine | 2 | 2024 | 129 | 0.250 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 2 | 2024 | 171 | 0.250 |
Why?
| | Lung Neoplasms | 1 | 2016 | 2201 | 0.220 |
Why?
| | Sulfonamides | 2 | 2024 | 445 | 0.220 |
Why?
| | Carcinoma, Mucoepidermoid | 1 | 2022 | 15 | 0.210 |
Why?
| | Salivary Gland Neoplasms | 1 | 2022 | 31 | 0.210 |
Why?
| | Gene Fusion | 1 | 2022 | 18 | 0.200 |
Why?
| | Translocation, Genetic | 2 | 2022 | 94 | 0.200 |
Why?
| | Lymphoproliferative Disorders | 1 | 2022 | 46 | 0.200 |
Why?
| | Immunophenotyping | 1 | 2022 | 276 | 0.190 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2022 | 72 | 0.190 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 97 | 0.180 |
Why?
| | Organ Transplantation | 1 | 2022 | 161 | 0.170 |
Why?
| | Epistaxis | 1 | 2018 | 11 | 0.160 |
Why?
| | Lymphadenopathy | 1 | 2018 | 8 | 0.160 |
Why?
| | Erythema | 1 | 2018 | 25 | 0.160 |
Why?
| | Myelodysplastic Syndromes | 1 | 2019 | 119 | 0.150 |
Why?
| | Forearm | 1 | 2018 | 114 | 0.150 |
Why?
| | Fusion Proteins, bcr-abl | 1 | 2018 | 61 | 0.150 |
Why?
| | Parotid Gland | 1 | 2017 | 25 | 0.150 |
Why?
| | Parotid Neoplasms | 1 | 2017 | 15 | 0.150 |
Why?
| | Clinical Laboratory Techniques | 1 | 2018 | 87 | 0.150 |
Why?
| | Cadherins | 1 | 2018 | 175 | 0.140 |
Why?
| | Combined Modality Therapy | 2 | 2019 | 1127 | 0.140 |
Why?
| | Spleen | 1 | 2018 | 486 | 0.140 |
Why?
| | Cysts | 1 | 2017 | 93 | 0.140 |
Why?
| | Neck | 1 | 2017 | 84 | 0.140 |
Why?
| | Humans | 15 | 2024 | 115039 | 0.130 |
Why?
| | Lymphoma | 1 | 2017 | 178 | 0.130 |
Why?
| | Phosphoproteins | 1 | 2018 | 298 | 0.130 |
Why?
| | Young Adult | 3 | 2022 | 10498 | 0.130 |
Why?
| | Teratoma | 1 | 2017 | 92 | 0.130 |
Why?
| | Codon | 1 | 2016 | 86 | 0.130 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2018 | 370 | 0.130 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2016 | 69 | 0.130 |
Why?
| | Fatal Outcome | 1 | 2016 | 285 | 0.120 |
Why?
| | Amino Acid Substitution | 1 | 2016 | 262 | 0.120 |
Why?
| | Ultrasonography | 1 | 2018 | 636 | 0.120 |
Why?
| | DNA Mutational Analysis | 1 | 2016 | 372 | 0.120 |
Why?
| | Adolescent | 4 | 2022 | 17862 | 0.120 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2019 | 520 | 0.120 |
Why?
| | Child | 4 | 2022 | 18407 | 0.120 |
Why?
| | Male | 8 | 2024 | 55730 | 0.110 |
Why?
| | Aged, 80 and over | 3 | 2024 | 6357 | 0.110 |
Why?
| | Pain | 1 | 2018 | 709 | 0.110 |
Why?
| | Sensitivity and Specificity | 1 | 2017 | 1715 | 0.100 |
Why?
| | Biopsy | 1 | 2016 | 1046 | 0.100 |
Why?
| | Tomography, X-Ray Computed | 2 | 2018 | 2341 | 0.100 |
Why?
| | Treatment Outcome | 3 | 2024 | 9122 | 0.090 |
Why?
| | Mouth Neoplasms | 1 | 2011 | 70 | 0.090 |
Why?
| | Prognosis | 3 | 2024 | 3334 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 2 | 2017 | 3116 | 0.080 |
Why?
| | Genes, Transgenic, Suicide | 1 | 2008 | 7 | 0.080 |
Why?
| | Mice, Inbred C3H | 1 | 2008 | 242 | 0.070 |
Why?
| | Neoplasms, Experimental | 1 | 2008 | 151 | 0.070 |
Why?
| | Genetic Vectors | 1 | 2008 | 291 | 0.070 |
Why?
| | Disease-Free Survival | 1 | 2008 | 617 | 0.070 |
Why?
| | Female | 5 | 2024 | 59611 | 0.070 |
Why?
| | Aged | 3 | 2024 | 19119 | 0.070 |
Why?
| | Adult | 3 | 2024 | 30655 | 0.060 |
Why?
| | Antigens, CD20 | 1 | 2022 | 28 | 0.050 |
Why?
| | Chromosome Aberrations | 1 | 2022 | 135 | 0.050 |
Why?
| | Gene Rearrangement | 1 | 2022 | 135 | 0.050 |
Why?
| | Retrospective Studies | 3 | 2024 | 12547 | 0.050 |
Why?
| | Cell Line, Tumor | 1 | 2008 | 2715 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2022 | 115 | 0.050 |
Why?
| | Polymerase Chain Reaction | 1 | 2024 | 999 | 0.050 |
Why?
| | Rituximab | 1 | 2022 | 150 | 0.050 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2022 | 310 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2019 | 4420 | 0.050 |
Why?
| | Trans-Activators | 1 | 2022 | 368 | 0.040 |
Why?
| | Remission Induction | 1 | 2019 | 233 | 0.040 |
Why?
| | Hepatocyte Growth Factor | 1 | 2018 | 33 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2018 | 299 | 0.040 |
Why?
| | Biopsy, Fine-Needle | 1 | 2017 | 64 | 0.040 |
Why?
| | Middle Aged | 3 | 2024 | 26827 | 0.040 |
Why?
| | Genetic Testing | 1 | 2019 | 380 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2018 | 590 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1646 | 0.030 |
Why?
| | Infant | 2 | 2019 | 7945 | 0.030 |
Why?
| | Proto-Oncogene Proteins | 1 | 2018 | 609 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2017 | 856 | 0.030 |
Why?
| | Mice | 1 | 2008 | 14927 | 0.020 |
Why?
| | Mouth Mucosa | 1 | 2011 | 79 | 0.020 |
Why?
| | Transcription Factors | 1 | 2018 | 1531 | 0.020 |
Why?
| | Cell Separation | 1 | 2011 | 291 | 0.020 |
Why?
| | Keratinocytes | 1 | 2011 | 216 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2019 | 5040 | 0.020 |
Why?
| | Animals | 1 | 2008 | 31867 | 0.020 |
Why?
| | Stem Cells | 1 | 2011 | 546 | 0.020 |
Why?
| | Child, Preschool | 1 | 2019 | 9093 | 0.020 |
Why?
| | Signal Transduction | 1 | 2018 | 4525 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2011 | 956 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2011 | 3896 | 0.010 |
Why?
|
|
Siegele's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|